Core Insights - The earnings season for Europe's largest pharmaceutical companies showed mixed results, but the focus is shifting towards future developments, particularly in 2026, which is expected to be a pivotal year following significant changes in 2025 [1][2] Industry Trends - Companies are facing a "patent cliff," where major drugs will lose exclusivity, leading to increased competition from generics [3] - There is a heightened emphasis on drug pipelines as companies aim to reassure investors about future growth despite impending patent expirations [4] Company Strategies - Novartis anticipates a loss of $4 billion in sales and profits in the first half of the year due to patent expirations but remains optimistic about growth driven by a strong pipeline [5] - AstraZeneca is confident in its pipeline, projecting 25 new blockbuster medicines by 2030 and aiming for $80 billion in revenue, up from $59 billion in 2025 [8] - Companies are increasingly looking towards mergers and acquisitions (M&A) to replenish their pipelines, with a focus on both smaller and larger deals [9][11] Market Dynamics - China is emerging as a significant source of innovation for pharmaceutical companies, with increased collaboration and deal-making with Chinese firms [13][15] - The market is evolving in terms of pricing strategies, particularly in response to U.S. and European pricing pressures, with companies considering various approaches to manage drug launches [16][17] Obesity Drug Market - The obesity drug market is becoming more consumer-oriented, with companies like Novo Nordisk and Eli Lilly facing increasing competition as new players enter the space [20] - AstraZeneca and Roche are developing new treatments to differentiate themselves in the crowded obesity market, focusing on convenience and improved tolerability profiles [21][23][24]

2026.02.13 本文字数：1066，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 投行杰富瑞在一份致客户的报告中表示，她可能不会出现在很多CEO潜在继任者的名单中，她在默克的 业绩没有达到前任高管的水平。 即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲 ...

即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前， 加之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 不过葛丽鹤在默克任职期间，该公司在新药开发方面遭遇了许多挫折，仅三款新药进入市场。此外，尽 管她在不同领域有着广泛的经验，但市 ...

智通财经APP获悉，法国制药巨头赛诺菲(SNY.US)即将上任的首席执行官、65 岁的贝伦·加里霍(Belén Garijo)面临一项重大任务：赢得投资者支持，加快这 家法国公司停滞不前的药物研发进程，并在美国总统唐纳德·特朗普执政期间应对疫苗怀疑论。 据接近加里霍的投资者、分析师及其他人士透露，她行事果敢、注重细节且执行力突出，但研发成果却表现参差不齐，其任期内公司股价更出现明显下跌。 值得关注的是，加里霍自2021年起便担任德国默克集团首席执行官。 "赛诺菲首席执行官的变动表明研发转型已经失败或进展过于缓慢，"赛诺菲投资者联合投资公司的投资组合经理马库斯·曼斯(Markus Manns)表示。"贝伦在 赛诺菲的首要任务将是提高研发产出效率。" 曼斯高度评价加里霍成功管理了业务横跨健康与科技领域的默克集团，并特别肯定她去年与美国总统唐纳德·特朗普达成的关键定价协议。不过他同时指 出，在默克集团经历数次研发挫折后，这位首席执行官亟需加速推进创新进程以应对挑战。 "她需要改善自己的研发业绩记录。" 替代哮喘重磅药物度普利尤单抗是重大挑战 开发新药一直是赛诺菲面临的最大问题。度普利尤单抗(Dupixent)占公司 ...

Core Insights - Reju, a textile recycling firm owned by Technip Energies, plans to build a polyester recycling plant in southwest France to address fast fashion's waste problem [1] - The new plant aims to convert used textiles into new polyester fibers, with similar projects planned in the Netherlands and the United States [1] - The textile recycling industry is still in its early stages, facing high costs and challenges in scaling operations [1] Company Developments - Reju's new plant in Lacq is expected to target around 50,000 metric tons per year of recycled polyester, with investments estimated between 300 million and 400 million euros ($355-475 million) per site [1] - CEO Patrik Frisk emphasized the mission to transform textile waste into valuable resources, highlighting the need for sustainable practices in the industry [1] - Several brands are reportedly lined up to sign purchase agreements with Reju, indicating potential demand for recycled materials [1] Industry Context - The production of polyester, primarily derived from petrochemicals, has surged in recent years, driven by its low cost and durability [1] - Fast fashion retailers like H&M and Inditex are investing in textile-to-textile recycling startups to enhance sustainability and comply with stricter regulations [1] - Currently, 98% of recycled polyester is sourced from plastic bottles, which has drawn criticism for diverting materials from established recycling loops [1]

Core Viewpoint - Sanofi's new CEO, Belén Garijo, faces significant challenges in revitalizing the company's drug pipeline and addressing investor concerns, particularly regarding the reliance on the eczema treatment Dupixent, which constitutes over 30% of revenues [1] Group 1: Leadership Transition - Belén Garijo, previously CEO of Merck KGaA, will become Sanofi's first female CEO and the only woman leading a large-cap global drugmaker after GSK's Emma Walmsley stepped down [1] - Garijo's appointment follows the resignation of Paul Hudson, whose efforts to turn around Sanofi were hindered by a lack of new blockbuster drugs, leading to a 25% decline in Sanofi's stock over the past year [1] Group 2: Drug Pipeline Challenges - Sanofi's primary challenge is to replace Dupixent, as the company has not identified a successor drug ahead of patent expirations in the early 2030s, which has negatively impacted share prices [1] - Vaccine sales, which account for nearly 20% of revenues, have also declined, exacerbated by a more skeptical attitude towards vaccines from the U.S. health administration [1] Group 3: R&D and Investor Expectations - Investors and analysts emphasize the need for Garijo to enhance R&D productivity, as her previous tenure at Merck KGaA was marked by mixed results in drug development, with only three new drugs launched [1] - Garijo is recognized for her operational execution and detail-oriented approach, but there are concerns about her ability to reinvigorate Sanofi's R&D department given her stronger background in operations than in scientific research [1]

Belén Garijo 拥有西班牙国籍，曾在医院工作六年，之后投身制药行业。她先是在雅培的研发部门工 作，随后在赛诺菲工作了 15 年。2011 年加入默克集团，并于 2021 年成为首席执行官。 来源：市场资讯 （来源：求实药社） 2 月 12 日，赛诺菲宣布，董事会决定不再续聘 Paul Hudson CEO 的职务，其将在 2026 年 2 月 17 日正 式卸任。同时，董事会任命了 Belén Garijo 作为新任 CEO，将在 2026 年 4 月 29 日集团股东大会结束后 正式就职。 另外，在 2026 年 2 月 17 日至 4 月 29 日期间，执行副总裁 Olivier Charmeil 将在过渡期间担任临时首席 执行官。 文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中 立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自 行承担全部。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][39]. Core Insights - The pharmaceutical sector has shown resilience, outperforming the overall market, with traditional Chinese medicine leading the gains [1][28]. - Roche's oral BTK inhibitor Fenebrutinib has demonstrated non-inferiority to Ocrelizumab in treating primary progressive multiple sclerosis (PPMS), marking a significant advancement in the treatment landscape [2][11]. - The global market for multiple sclerosis (MS) treatment exceeds $20 billion, with unmet needs in PPMS due to limited treatment options [3][25]. Summary by Sections Market Performance - The overall A-share market declined by 1.3%, while the biopharmaceutical sector increased by 0.1%, indicating a stronger performance relative to the market [1][28]. - Specific segments within the biopharmaceutical sector showed varied performance, with traditional Chinese medicine rising by 2.6% [1][28]. Clinical Data and Drug Development - Roche's Fenebrutinib trial for PPMS included 985 patients and achieved its primary endpoint, showing a 12% reduction in disease progression risk compared to Ocrelizumab [2][11][24]. - The safety profile of Fenebrutinib was comparable to Ocrelizumab, with a similar incidence of adverse events [22][24]. Company Earnings Forecast and Investment Recommendations - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, are rated as "Outperform" with projected earnings growth [4][39]. - Mindray Medical is highlighted for its strong R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [39]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 37.31x, compared to the overall A-share market at 21.98x [35][36]. - Specific segments like chemical pharmaceuticals and biological products have higher valuations, indicating investor confidence in these areas [35][36].

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting the key trends and catalysts that influence market valuations [1] Group 1 - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, offers detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma industries [1] - Haggerston BioHealth provides insights for both novice and experienced investors, including catalysts to monitor, buy and sell ratings, product sales forecasts, and integrated financial statements [1] - The group also conducts discounted cash flow analysis and market-by-market analysis for major pharmaceutical companies [1]

Leadership Change - Sanofi has announced the appointment of Belén Garijo as the new CEO, succeeding Paul Hudson, whose contract will not be renewed [1] - Garijo, currently the CEO of Merck KGaA, will assume her new role on April 29, 2026, after a five-year tenure at Merck KGaA [2] Financial Performance - Sanofi's vaccine revenue dropped by 5% in 2025, generating €7.9 billion compared to €8.3 billion in 2024, while overall net sales grew by 9.9% at constant exchange rates to reach €43.6 billion ($51.7 billion) [4] - The company is preparing for the loss of patent protection for Dupixent, which generated €14.7 billion last year [5] Challenges and Pipeline Issues - Sanofi is facing challenges in the US vaccine sector due to policy changes under the Trump administration, impacting immunization recommendations and new candidate approvals [3] - Recent pipeline disappointments include FDA rejections and failures in multiple sclerosis treatments, as well as mixed results for COPD candidates [6] Strategic Focus - Garijo's primary focus will be on enhancing the productivity, governance, and innovation capacity of Sanofi's R&D [7]